Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) EPS (Weighted Average and Diluted): 2020-2024

Historic EPS (Weighted Average and Diluted) for Seres Therapeutics (MCRB) over the last 5 years, with Dec 2024 value amounting to -$0.81.

  • Seres Therapeutics' EPS (Weighted Average and Diluted) fell 91.92% to $0.94 in Q3 2025 from the same period last year, while for Sep 2025 it was $16.29, marking a year-over-year increase of 964.71%. This contributed to the annual value of -$0.81 for FY2024, which is 45.64% up from last year.
  • Seres Therapeutics' EPS (Weighted Average and Diluted) amounted to -$0.81 in FY2024, which was up 45.64% from -$1.49 recorded in FY2023.
  • Seres Therapeutics' EPS (Weighted Average and Diluted)'s 5-year high stood at -$0.72 during FY2021, with a 5-year trough of -$2.31 in FY2022.
  • In the last 3 years, Seres Therapeutics' EPS (Weighted Average and Diluted) had a median value of -$1.49 in 2023 and averaged -$1.54.
  • Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first plummeted by 220.83% in 2022, then soared by 45.64% in 2024.
  • Over the past 5 years, Seres Therapeutics' EPS (Weighted Average and Diluted) (Yearly) stood at -$1.12 in 2020, then surged by 35.71% to -$0.72 in 2021, then plummeted by 220.83% to -$2.31 in 2022, then soared by 35.50% to -$1.49 in 2023, then soared by 45.64% to -$0.81 in 2024.